Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
NASDAQ:MBOT

Microbot Medical 3/27/2026 Earnings Report

Microbot Medical logo
$2.12 -0.01 (-0.28%)
As of 12:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Microbot Medical EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Microbot Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Microbot Medical Announcement Details

Quarter
Date
3/27/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Microbot Medical's next earnings date is estimated for Wednesday, May 13, 2026, based on past reporting schedules.

Conference Call Resources

Microbot Medical Earnings Headlines

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
May 5 at 3:34 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-across-key-territories-including-two-access-pvi-pivotal-clinical-trial-sites-1036106255
Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
May 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287696/0/en/microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-across-key-territories-including-two-access-pvi-pivotal-clinical-trial-sites.html
The chokepoint supplier behind SpaceX's $1.75 trillion empire
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.tc pixel
May 8 at 1:00 AM  |  Behind the Markets (Ad)
Microbot Medical (NASDAQ:MBOT) Stock Rating Lowered by Wall Street Zen
May 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30752940
Microbot Medical Inc. (NASDAQ:MBOT) Receives $7.50 Consensus PT from Analysts
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30751919
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284840/0/en/microbot-medical-announces-the-addition-of-senior-commercial-executive-with-proven-track-record-to-accelerate-commercial-readiness-in-europe-the-middle-east-and-asia-emea.html
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease. The endoluminal platform targets gastrointestinal and urogenital tracts, employing swallowable or catheter-deployed microbots to biopsy tissue, administer local therapy or assist in endoscopic procedures.

Headquartered in Ra’anana, Israel, with U.S. operations in Boston, Massachusetts, Microbot Medical collaborates with leading academic and clinical research centers to advance its pipeline through preclinical studies and early-stage human trials. Under the leadership of CEO Ohad Arazi, the company seeks regulatory approvals and strategic partnerships to bring its microbot platforms to global markets in Europe, North America and Asia.

View Microbot Medical Profile
Earnings Tools